NCT03916627
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03916627
Title Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.